Conflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now
Up until now, Lars Rebien Sørensen has refrained from taking on board roles at pharmaceutical companies due to the risk of conflicts of interest. Now, the chairman of the Novo Nordisk Foundation will be taking on the role of chairman of the board at Ferring, although he highlights one possible conflict of interest with Denmark's largest pharmaceutical giant.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ferring appoints Lars Rebien Sørensen as new chairman
For subscribers
